# US 2021/0171650 A1 · Methods of administering anti-cd38 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171650 A1
- Document ID: US20210171650A1
- Status: Published application
- Kind: A1
- Application number: 15/931,466
- Filed: 2020-05-13
- Published: 2021-06-10
- Earliest claimed: 2019-05-14
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Heloise AUDAT; Sylvia MARION; Frank CAMPANA ZAMBRANO
- Web page: https://patentgrep.com/patent/US20210171650A1

## CPC

- A61P 35/02: specific for leukemia
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are methods of treating a human individual having multiple myeloma that comprise administering to the individual 10 mg/kg isatuximab via intravenous infusion, wherein the volume of each infusion of 10 mg/kg isatuximab is 250 ml. Also provided are methods of treating a human individual having multiple myeloma that comprise administering an anti-CD38 antibody in 28-day cycles, wherein the anti-CD38 antibody is administered on Days 1, 8, 15, and 22 of a first 28-day cycle, wherein the CD38-antibody is administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle; and wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg or 20 mg/kg.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of administering an anti-CD38 antibody to a human individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual at least a first dose of the anti-CD38 antibody by intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody is isatuximab.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 2)

The method of claim 2, wherein the first dose of the anti-CD38 antibody is administered to the individual:
(a) at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused; or
(b) at an infusion rate of 12.5 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

### Claim 6

(canceled)

### Claim 7 (depends on 2)

The method of claim 2, comprising administering to the individual at least a second dose of the anti-CD38 antibody by intravenous infusion, wherein the second dose of anti-CD38 antibody is administered to the individual:
(a) at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused;
(b) at an infusion rate of 50 mL/hour for a first 30 minutes, 100 mL/hour for a second 30 minutes, 200 mL for the third 30 minutes, and 300 mL/hour after the third 30 minutes until the 250 ml volume is infused; or
(c) at an infusion rate of 25 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

### Claim at position 7

8-10. (canceled)

### Claim 11 (depends on 7)

The method of claim 7, comprising administering to the individual at least a third dose of the anti-CD38 antibody by intravenous infusion, wherein the third dose of the anti-CD38 antibody is administered to the individual at:
(a) an infusion rate of 200 ml/hour until the 250 ml volume is infused; or
(b) at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

### Claim at position 9

12-13. (canceled)

### Claim 14 (depends on 11)

The method of claim 11, comprising administering to the individual a fourth dose of the anti-CD38 antibody by intravenous infusion, wherein the fourth dose of the anti-CD38 antibody is administered is administered to the individual:
(a) at an infusion rate of 200 ml/hour until the 250 ml volume infused; or
(b) at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

### Claim at position 11

15-16. (canceled)

### Claim 17 (depends on 14)

The method of claim 14, wherein the anti-CD38 antibody is administered in a first 28-day cycle, wherein the first dose of the anti-CD38 antibody is administered on Day 1, the second dose of the anti-CD38 antibody is administered on Day 8, the third dose of the anti-CD38 antibody is administered on Day 15, and the fourth dose of the anti-CD38 antibody is administered on Day 22 the first 28-day cycle.

### Claim 18 (depends on 14)

The method of claim 14, comprising administering to the individual one or more subsequent doses of the anti-CD38 antibody by intravenous infusion following the fourth dose, wherein the one or more subsequent doses of the anti-CD38 antibody are administered to the individual:
(a) at an infusion rate of 200 ml/hour until the 250 ml volume infused; or
(b) at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

### Claim at position 14

19-20. (canceled)

### Claim 21 (depends on 18)

The method of claim 18, wherein the anti-CD38 antibody is administered in one or more subsequent 28-day cycles following the first 28-day cycle, wherein each of the one or more subsequent doses of the anti-CD38 antibody following the fourth dose of the anti-CD38 antibody are administered on Days 1 and 15 of each of the one or more subsequent 28-day cycles following the first 28-day cycle.

### Claim 22

(canceled)

### Claim 23

A method of administering an anti-CD38 antibody to a human individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual at least three doses of the anti-CD38 antibody by intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody is isatuximab;
wherein the first dose of the anti-CD38 antibody is administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused;
wherein the second dose of the anti-CD38 is administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused; and
wherein the third dose of the anti-CD38 is administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

### Claim at position 18

24-25. (canceled)

### Claim 26 (depends on 23)

The method of claim 23, further comprising administering to the individual one or more subsequent doses of the anti-CD38 antibody following the third dose, wherein the one or more subsequent doses of the anti-CD38 antibody are administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.

### Claim at position 20

27-47. (canceled)

### Claim 48

A method of safely administering an anti-CD38 antibody to a human individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual at least a first dose of the anti-CD38 antibody via intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the first dose is infused over a duration of about 1.5 and about 6.5 hours, and wherein the anti-CD38 antibody is isatuximab.

### Claim at position 22

49-50. (canceled)

### Claim 51 (depends on 48)

The method of claim 48, comprising administering at least a second dose of the anti-CD38 antibody to the individual via intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the second dose is infused over a duration of about 0.5 and 3.5 hours.

### Claim 52 (depends on 51)

The method of claim 51, comprising administering at least a third dose of the anti-CD38 antibody to the individual via intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the third dose is infused over a duration of about 0.5 and 1.5 hours.

### Claim 53 (depends on 7)

The method of claim 7, wherein the rate of infusion reactions (IR) from the intravenous infusion of the second dose of the anti-CD38 antibody is reduced compared to the IR from the intravenous infusion of the first dose of the anti-CD38 antibody.

### Claim at position 26

54-59. (canceled)

### Claim 60

A method of treating a human individual having multiple myeloma, comprising administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone,
wherein the anti-CD38 antibody is isatuximab and is administered in 28-day cycles;
wherein the anti-CD38 antibody is administered on Days 1, 8, 15, and 22 of a first 28-day cycle;
wherein the anti-CD38 antibody is administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle;
and wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg in a volume of 250 ml or 20 mg/kg.

### Claim at position 28

61-70. (canceled)

### Claim 71 (depends on 2)

The method of claim 2, wherein the individual has a respiratory disorder, thoracic disorder, and/or mediastinal disorder.

### Claim 72 (depends on 71)

The method of claim 71, wherein the respiratory disorder is chronic obstructive pulmonary disorder (COPD), asthma, or bronchospasm.

### Claim at position 31

73-84. (canceled)

### Claim 85

An intravenous bag containing between about 360 mg and 1600 mg of an anti-CD38 antibody in a volume of 250 ml, wherein the wherein the anti-CD38 antibody is isatuximab.

### Claim 86 (depends on 11)

The method of claim 11, wherein the rate of infusion reactions (IR) from the intravenous infusion of the third dose of the anti-CD38 antibody is reduced compared to the IR from the intravenous infusion of the first dose of the anti-CD38 antibody.

### Claim 87 (depends on 14)

The method of claim 14, wherein the rate of infusion reactions (IR) from the intravenous infusion of the fourth dose of the anti-CD38 antibody is reduced compared to the IR from the intravenous infusion of the first dose of the anti-CD38 antibody.
